Fig. 10
From: Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma
Gene mutation, tumour mutational burden and microsatellite instability, along with drug sensitivities analyses. (A-B) Landscape of gene mutation in PCa (A) and both risk group (B), respectively; (C-D) Association between the cuproptosis-related lncRNA signature and tumour mutational burden (C) as well as microsatellite instability (D); (E–F) Drug sensitivities analyses of bicalutamide (E) and docetaxel (F) in both risk group, ns: p > 0.05; *: p < 0.05; **: p < 0.01; ***: p < 0.001